CZ34480U1 - A product with effects against psoriasis - Google Patents
A product with effects against psoriasis Download PDFInfo
- Publication number
- CZ34480U1 CZ34480U1 CZ2020-37833U CZ202037833U CZ34480U1 CZ 34480 U1 CZ34480 U1 CZ 34480U1 CZ 202037833 U CZ202037833 U CZ 202037833U CZ 34480 U1 CZ34480 U1 CZ 34480U1
- Authority
- CZ
- Czechia
- Prior art keywords
- product
- effects against
- lysine hydrochloride
- psoriasis
- against psoriasis
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims description 3
- 201000004681 Psoriasis Diseases 0.000 title description 5
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940030999 antipsoriatics Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
Přípravek s účinky proti lupéncePreparation with effects against psoriasis
Oblast technikyField of technology
Technické řešení se týká přípravku pro použití hydrochloridu L-lysinu pro léčbu nebo prevenci lupénkyThe technical solution relates to a preparation for the use of L-lysine hydrochloride for the treatment or prevention of psoriasis
Dosavadní stav technikyPrior art
Lupénka je kožní onemocnění, vykazující řadu různých podob vyznačující se tvorbou šupinatých červených skvrn na rozsáhlých plochách těla. Jedná se zpravidla o chronické onemocnění, které bývá dáváno do souvislosti s určitou genetickou podmíněností. Léčba postižených pacientů je obvykle komplikovaná a nákladná, přičemž léčebný účinek nemusí být vždy dosažen. Pokud toto onemocnění vstoupí do progresivní fáze, může rovněž zasahovat klouby a způsobovat kruté bolesti a omezení pacientovy pohyblivosti. Standardní léčebné postupy se v poslední době významně nezměnily a běžnými způsoby ošetření stále zůstávají procesy světelné terapie, laseru a aplikace mastí, použití např. kortikoidů a čemouhelného dehtu. Nejúčinnější je biologická léčba, která je však velmi nákladná a aplikuje se pouze se středně těžkými a těžkými formacemi nemoci.Psoriasis is a skin disease with a number of different forms characterized by the formation of scaly red spots on large areas of the body. It is usually a chronic disease that is associated with a certain genetic condition. The treatment of affected patients is usually complicated and expensive, and the therapeutic effect may not always be achieved. If the disease enters a progressive phase, it can also affect the joints and cause severe pain and limited patient mobility. Standard treatments have not changed significantly recently, and light therapy, laser, and ointment applications such as corticoids and coal tar remain common treatments. The most effective is biological treatment, which is very expensive and is applied only with moderate and severe formations of the disease.
Podstata technického řešeníThe essence of the technical solution
Předkládané řešení je založeno na překvapivém zjištění původce, že v průběhu užívání přípravku hydrochloridu L-lysinu s cílem zvýšení imunity, bylo shledáno, že došlo k vymizení nebo významnému zmírnění onemocnění pokožky souvisejícího se symptomy lupénky, přestože užívání hydrochloridu L-lysinu nebylo zacíleno na kožní onemocnění, ale na zvýšení imunity.The present solution is based on the inventor's surprising finding that while taking L-lysine hydrochloride to increase immunity, it was found that the skin disease associated with psoriasis symptoms disappeared or significantly alleviated, although L-lysine hydrochloride use was not targeted at the skin. disease, but to increase immunity.
Příklad uskutečnění technického řešeníExample of implementing a technical solution
Ložiska se vyskytovala v následujících oblastech: na hřbetech ruky, na stehnech, ve vlasech, v oblasti bederní páteře a pod nehty. Ke zmírnění onemocnění došlo na loktech. Pozitivní výsledky se dostavily po 2 až 3 měsících orálního užívání hydrochloridu L-lysinu v množství 1 g/denně.The lesions occurred in the following areas: on the backs of the hand, on the thighs, in the hair, in the lumbar spine and under the nails. The disease was alleviated on the elbows. Positive results were obtained after 2 to 3 months of oral administration of L-lysine hydrochloride at a rate of 1 g / day.
Při léčbě byl používán potravinový doplněk L-lysin 1000 mg ve formě tablet (výrobce Natures Aid Ltd, GB dodávaný na internetu nebo jej lze objednat v lékárně). Přípravek má následující složení: hydrochlorid L-lysinu 1000 mg, mikrokrystalická celulóza (plnidlo), di-fosforečnan vápenatý (plnidlo), potah tablety (hydroxypropylmethylcelulóza, glycerin, sójový lecitin, dextróza), protispékavé látky (stearát hořečnatý z rostlinného zdroje, oxid křemičitý).The dietary supplement L-lysine 1000 mg in the form of tablets (manufactured by Natures Aid Ltd, GB supplied online or can be ordered from a pharmacy) was used in the treatment. The preparation has the following composition: L-lysine hydrochloride 1000 mg, microcrystalline cellulose (filler), calcium diphosphate (filler), tablet coating (hydroxypropylmethylcellulose, glycerin, soy lecithin, dextrose), anti-caking agents (magnesium stearate from a vegetable source, silica) ).
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2020-37833U CZ34480U1 (en) | 2020-07-31 | 2020-07-31 | A product with effects against psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2020-37833U CZ34480U1 (en) | 2020-07-31 | 2020-07-31 | A product with effects against psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ34480U1 true CZ34480U1 (en) | 2020-10-23 |
Family
ID=73015454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ2020-37833U CZ34480U1 (en) | 2020-07-31 | 2020-07-31 | A product with effects against psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CZ (1) | CZ34480U1 (en) |
-
2020
- 2020-07-31 CZ CZ2020-37833U patent/CZ34480U1/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2292643T3 (en) | TREATMENT OF THE COLLATERAL EFFECTS OF STATIN. | |
| JPH0640904A (en) | Medicinal composition | |
| CN102389423A (en) | Medicinal composition containing ibuprofen sodium salt | |
| WO2012145369A1 (en) | Compositions and methods for nutritional supplementation | |
| IT8922725A1 (en) | USE OF IMMUNOMODULANTS AS SYNERGIC AGENTS OF CHEMOTHERAPY IN CANCER THERAPY | |
| JP7206223B2 (en) | Substances for prophylactic and/or supportive treatment of Parkinson's disease | |
| JP2016505050A5 (en) | ||
| BR112017026417B1 (en) | FORMULATION FOR THE TREATMENT OF MOUTH, THROAT AND RESPIRATORY TRACT DISORDERS | |
| US3557292A (en) | Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine | |
| JP7291079B2 (en) | How to reduce symptoms of PMS | |
| RU2015119377A (en) | DRUG FORMS FOR QUICK COUPLING OF PARKINSON'S DISEASE | |
| UA91028C2 (en) | Use of lavender oil for the prophylaxis and treatment of neuro asthenia, somatization disorders and other diseases associated with stress | |
| CN107137417B (en) | Pharmaceutical composition for treating cachexia and application thereof | |
| EP1021087A1 (en) | Serotonin containing formulation for oral administration and method of use | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
| CZ34480U1 (en) | A product with effects against psoriasis | |
| WO2018117103A1 (en) | Composition for ameliorating peripheral nerve disorders | |
| ES2963784T3 (en) | Use of delgocitinib for the treatment of chronic hand eczema | |
| CN101518521B (en) | New medical application of cedrol | |
| JP5963791B2 (en) | Composition used to alleviate symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder | |
| HU207800B (en) | Process for producing composition for improving condition and for treating different illnesses | |
| WO2019094500A1 (en) | Compositions and methods for the treatment of skin lesions | |
| MX2022012693A (en) | Composition comprising methylfolate. | |
| KR20230040405A (en) | Injection composition for lipolysis | |
| KR100766904B1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING gamma;-POLYGLUTAMIC ACID FOR ALLEVIATING AND TREATING ALLERGIES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG1K | Utility model registered |
Effective date: 20201023 |